Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Phio Pharmaceuticals Corp.

NASDAQ: PHIO · Life Sciences · 8 alerts · CIK 1533040

Share price
$0.7522Close, Nov 16
Market cap
$8.99M
Shares outstanding
11.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Phio Pharmaceuticals Corp. filings on SEC EDGAR ↗

11:19 AM ET Form 4
Insider Buying

Phio Pharmaceuticals Insider Ronald Todd Plott Buys $15.2K of Stock

Ronald Todd Plott bought 18,300 shares of Phio Pharmaceuticals Corp. at $0.83 a share, worth $15.2K in total on Nov 9, 2026. Shares held after the trade: 60,300 (+43.6%).

Value
$15.2K
Shares
18,300
Price
$0.8300
Holding change
+43.6%
Trade date
Nov 9, 2026
11:17 AM ET Form 4
Insider Buying

Phio Pharmaceuticals Chairman, Pres. & CEO Robert J. Bitterman Buys $20.5K of Stock

Robert J. Bitterman, Chairman, Pres. & CEO, bought 25,000 shares of Phio Pharmaceuticals Corp. at $0.82 a share, worth $20.5K in total on Nov 9, 2026. Shares held after the trade: 789,871 (+3.3%).

Value
$20.5K
Shares
25,000
Price
$0.8200
Role
Chairman, Pres. & CEO
Holding change
+3.3%
Trade date
Nov 9, 2026
4:17 PM ET 8-K
Financial Results

Phio Pharmaceuticals Financial Results

Phio Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $10.6 million. The company achieved key milestones for its PH-762 program, including the completion of commercial-scale cGMP manufacturing and the submission of Phase 1b clinical data to the FDA in preparation for a Phase 2b study initiation expected in Q1 2027.

Term
Q3 2026

“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation. Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”

Robert J. Bitterman, President and Chief Executive Officer
4:17 PM ET 10-Q
Financial Results

Phio Pharmaceuticals Q3 2026 Results: Net Loss of $4.16M, Loss Widens

Phio Pharmaceuticals Corp. reported a net loss of $12.3 million for the nine months ended September 30, 2026, compared to $6.3 million in the prior year period, primarily driven by a significant increase in research and development expenses. As of September 30, 2026, the company held $10.6 million in cash and cash equivalents, down from $21.0 million at the end of 2025.

Key figure
Net loss $4.16M
8:42 AM ET 8-K
Business Update

Phio Pharmaceuticals Business Update

Phio Pharmaceuticals successfully completed its first commercial-scale cGMP batch of PH-762 drug substance, a key manufacturing milestone. This achievement validates the company's supply chain readiness and supports the planned initiation of a Phase 2b clinical trial in the first quarter of 2027.

4:03 PM ET 8-K
Shareholder Meeting

Phio Pharmaceuticals Shareholder Meeting

Phio Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 28, 2026, where shareholders elected six directors and ratified Grant Thornton, LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Long Term Incentive Plan, increasing the number of shares available for issuance by 1,500,000 shares.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.